Across TCGA pan-cancer cohorts, VSTM5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated VSTM5 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher VSTM5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VSTM5 expression acts as an unfavorable survival marker.

SARC and ACC are the cancer types where VSTM5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.241	0.766	.022	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: VSTM5 tumor-vs-normal RNA expression · all VSTM5 data types